4/A: TENX Director Amends Insider Stock Purchase Filing

A Tenax Therapeutics director amended a Form 4 filing to correct the ownership form of 1,993 shares acquired indirectly through Meadowlark Management, LLC.

Summary

• An amendment to a Form 4 filing was submitted by June Sherie Almenoff, a Director of Tenax Therapeutics, Inc.
• The amendment corrects the ownership form for 1,993 shares of common stock previously reported as directly owned, clarifying they are indirectly owned.
• The shares were acquired through Meadowlark Management, LLC.
• On November 17, 2025, 93 shares were acquired at $7.15 per share.
• On November 18, 2025, 1,900 shares were acquired at a weighted average price of $7.5157 per share, with prices ranging from $7.45 to $7.70.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.
• The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.

Sentiment

Score: 7

Explanation: The filing indicates insider buying by a director, which is generally a positive signal of confidence in the company's future. The amendment itself is a minor correction to ownership form, not a negative event.

Positives

• A director, June Sherie Almenoff, acquired 1,993 shares of common stock, indicating insider confidence in the company.
• The transactions were executed under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy.

Negatives

• NA

Risks

• NA

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This filing is a standard insider transaction disclosure and does not provide broader industry context or trends.

Related Party Transactions

• Acquisition of 1,993 shares indirectly through Meadowlark Management, LLC, where the reporting person disclaims beneficial ownership except to the extent of her pecuniary interest.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive sign of confidence from a director, potentially influencing investor sentiment.
• Management: The correction in the filing demonstrates adherence to SEC reporting requirements.

Key Dates

Recommendation

The filing indicates a director's increased indirect stake in the company, which is a positive signal of confidence. However, this single insider transaction, even with its positive implications, is typically not sufficient on its own to warrant a 'buy' or 'strong buy' recommendation without a more comprehensive analysis of the company's financials, strategic outlook, and market conditions. It reinforces a 'hold' position for existing investors and suggests further due diligence for potential investors.

Keywords

Tenax Therapeutics, TENX, Form 4/A, Insider Trading, Director Stock Purchase, June Sherie Almenoff, Beneficial Ownership, SEC Filing, Equity Acquisition, Rule 10b5-1